跳至主要内容
临床试验/CTRI/2024/05/067153
CTRI/2024/05/067153尚未招募Unknown

POSEIDON – Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure

ovo Nordisk AS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.
  • 2. Age 18 years or above at the time of signing the informed consent.
  • 3. Presence of ASCVD and/or HF.
  • 4. Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).

排除标准

  • 1. Previous participation in this study. Participation is defined as having given informed
  • consent in this study.
  • 2. Current participation (i.e., signed informed consent) in any other interventional clinical
  • 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of
  • chronic disease with hospitalization).
  • 4. Clinical evidence, or suspicion of, active infection within the last 60 days.
  • 5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding
  • or cooperation

研究者

发起方
ovo Nordisk AS

相似试验